Baloney. Just flat-out baloney. MYDX is exactly where it should be.
All of this stuff about “clinical trials,” Dr. Coffee Enema and the other ambitions MYDX has laid out? They cost money, lots of money. Probably the reason AeroDX, AquaDX and OrganaDX are still not available after nearly two years.
MYDX showed in its 2017 financials a downward trend in revenue. They aren’t getting money from the bank down the street, they’re getting money from Wall Street. Specifically, dilution. When sales are woeful, dilution is the only way companies in this sector can raise more money. And a company must spend in order to prosper.
This company has played the victim card long enough. There should be more investors asking Yazbeck why he is paying rent in an affluent area of San Diego and has an extremely generous compensation package at a time when the company sorely needs revenue.
This “MYDX is undervalued” narrative is a load of crap.
